By Michele Maatouk
Date: Tuesday 31 Mar 2026
(Sharecast News) - Shares in Apellis Pharmaceuticals rocketed on Tuesday after it agreed to be bought by Biogen in a $5.6bn deal.
| Currency | US Dollars |
| Share Price | $ 190.20 |
| Change Today | $ -2.75 |
| % Change | -1.43 % |
| 52 Week High | $201.89 |
| 52 Week Low | $122.68 |
| Volume | 187,174 |
| Shares Issued | 146.80m |
| Market Cap | $27,921m |
| RiskGrade | 259 |
| Strong Buy | 8 |
| Buy | 6 |
| Neutral | 19 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 34 |

| Time | Volume / Share Price |
| 11:11 | 100 @ $190.20 |
| 11:11 | 100 @ $190.19 |
| 11:11 | 100 @ $190.19 |
| 11:11 | 100 @ $190.19 |
| 11:11 | 100 @ $190.19 |
You are here: research